Allogene Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 06/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $22,000 | $95,000 | — | — |
| Research and development | $150.2M | $192.3M | $242.9M | — | — |
| Operating expenses | $209.3M | $273.2M | $327.8M | — | — |
| Operating income | -$209.3M | -$273.2M | -$327.7M | — | — |
| Interest expense | $1.1M | $181,000 | $0 | — | — |
| Pretax income | -$190.9M | -$257.1M | -$327.3M | — | — |
| Income tax expense | $0 | $443,000 | $0 | — | — |
| Net income | -$190.9M | -$257.6M | -$327.3M | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $51.7M | $75.2M | $83.2M | $69.2M | $154.8M |
| Current assets | $257.7M | $303.4M | $459.1M | $473.5M | $502.1M |
| Total assets | $415.9M | $548.7M | $642.8M | $713.4M | $773.0M |
| Current liabilities | $32.5M | $35.5M | $37.1M | $37.5M | $54.6M |
| Total liabilities | $123.4M | $126.5M | $130.6M | $132.8M | $151.6M |
| Stockholders' equity | $292.5M | $422.2M | $512.2M | $580.6M | $621.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$149.2M | -$200.3M | -$237.7M | — | — |
| Depreciation and amortization | $12.4M | $13.6M | $14.2M | — | — |
| Stock-based compensation | $37.6M | $51.7M | $66.0M | — | — |
| Capital expenditure | $386,000 | $694,000 | $1.5M | — | — |
| Free cash flow | -$149.6M | -$201.0M | -$239.2M | — | — |
| Impairments | $2.4M | $15.7M | $13.2M | — | — |
Shares outstanding 345.2M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.